Equities

Cenra Inc

3716:TAI

Cenra Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)38.75
  • Today's Change0.10 / 0.26%
  • Shares traded172.62k
  • 1 Year change-15.58%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cenra Inc is a Taiwan-based company mainly engaged in the provision of general investment related businesses. Through its subsidiary, the Company conducts the development, manufacturing and sales of pharmaceuticals, agricultural and livestock drugs, personal hygiene and health products and the import and sale of medical instruments. Its subsidiaries’ products are pharmaceuticals and health products, including human medicines, such as prescription and indicated drugs, over-the-counter medicines, and disease treatment products; medical equipment, such as blood pressure monitors, blood glucose meters, and artificial joints; animal medicines, supplementary feeds, and feed additives, providing animal treatment, disease prevention, and nutritional supplement products; daily necessities, such as toothpaste, tooth powder, mouthwash and other oral hygiene and health products, hand cleansers, dry hand sanitizers, shower gels, medicated soaps and other lotion products, skin care series and other.

  • Revenue in TWD (TTM)8.87bn
  • Net income in TWD355.20m
  • Incorporated2024
  • Employees1.40k
  • Location
    Cenra IncTAIPEI 100TaiwanTWN
  • Phone+886 223124200
  • Fax+886 223615143
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Phytohealth Corp166.83m-68.45m3.59bn84.00--1.84--21.49-0.3446-0.34460.849.820.07050.60844.64---4.22-5.66-5.07-7.3140.8947.70-59.90-92.9126.47--0.0105--19.958.6240.67---40.76--
Nang Kuang Pharmaceutical Co Ltd2.09bn110.65m4.49bn552.0040.671.9815.352.151.091.0920.7222.520.5711.898.07--3.026.754.479.6433.1434.775.2812.220.631214.420.158782.7410.816.92-43.6314.4119.5110.76
Cenra Inc8.87bn355.20m5.78bn1.40k32.541.568.240.6511.191.1929.7324.900.70272.225.63--2.833.694.034.9636.7936.564.025.500.7959--0.294352.771.402.50-32.51-2.723.57-8.97
Sinphar Pharmaceutical Co Ltd3.01bn361.33m5.95bn984.0015.271.7710.111.982.152.1517.9318.610.48642.286.06--5.71-0.01477.67-0.020339.0237.4911.74-0.03441.4437.220.359979.703.725.9867.01111.883.3158.49
Formosa Pharmaceuticals Inc133.70m-298.43m5.98bn----5.92--44.75-2.22-2.220.99637.540.0803--1.61---17.91-40.34-19.62-44.2186.96---223.16-2,488.28----0.0277--2,270.49--20.75---42.98--
Panion & BF Biotech Inc2.01bn101.27m7.62bn321.0075.314.1127.953.791.181.1823.4221.620.61851.739.66--3.124.084.825.6352.6652.375.045.930.869910.620.287111.06-21.545.96-57.65-13.4735.39-3.23
Data as of Sep 20 2024. Currency figures normalised to Cenra Inc's reporting currency: Taiwan Dollar TWD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.